The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| LIVN | +1.32% | +2.32% | +0.46% | +352% |
| S&P | +18.33% | +108.18% | +15.79% | +1,439% |
LivaNova Plc is a global medical technology company, which engages in the development and delivery of therapeutic solutions for the benefit of patients, healthcare professionals, and healthcare systems. It operates through the Cardiopulmonary and Other segments. The Cardiopulmonary segment is involved in the development, production and sale of cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, and related accessories. The Other segment includes heart valves business and corporate shared service expenses for finance, legal, human resources, information technology, and corporate business development. The company was founded in 1987 and is headquartered in London, the United Kingdom.
These stocks lost ground even as the broader market posted solid gains.
The medical-device company posted tepid preliminary first-quarter revenue.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $352.52M | 10.7% |
| Gross Profit | $238.99M | 8.5% |
| Gross Margin | 67.79% | -1.4% |
| Market Cap | $2.45B | -17.3% |
| Market Cap / Employee | $0.85M | 0.0% |
| Employees | 2.9K | 0.0% |
| Net Income | $27.16M | 66.3% |
| EBITDA | $67.47M | 14.7% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $593.64M | -6.2% |
| Accounts Receivable | $220.20M | 9.6% |
| Inventory | 165.3 | 6.9% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $391.27M | -39.7% |
| Short Term Debt | $91.51M | 220.1% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -8.52% | -7.8% |
| Return On Invested Capital | -6.03% | 2.5% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $47.77M | 53.1% |
| Operating Free Cash Flow | $62.92M | 45.1% |
| Metric | Q4 2023 | Q3 2024 | Q4 2024 | YoY Change | |
|---|---|---|---|---|---|
| Price to Earnings | 160.48 | 123.28 | 40.33 | - | |
| Price to Book | 2.18 | 1.92 | 1.62 | 2.37 | -2.34% |
| Price to Sales | 2.32 | 2.03 | 1.68 | 1.88 | -24.20% |
| Price to Tangible Book Value | 10.19 | 8.98 | 6.41 | 68.58 | 352.33% |
| Price to Free Cash Flow TTM | 26.39 | 18.64 | 14.69 | 15.19 | -56.72% |
| Enterprise Value to EBITDA | 49.74 | 49.74 | -7.01 | 34.86 | -32.50% |
| Free Cash Flow Yield | 3.8% | 5.4% | 6.8% | 6.6% | 131.07% |
| Return on Equity | 1.9% | 4.9% | -19.7% | -17.9% | 1232.70% |
| Total Debt | $679.79M | $676.77M | $677.85M | $482.78M | -28.74% |
LIVN earnings call for the period ending September 30, 2021.
LIVN earnings call for the period ending June 30, 2021.
LIVN earnings call for the period ending March 31, 2021.
LIVN earnings call for the period ending December 31, 2020.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
